Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2018-10-22 Regulatory Filings
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Penthrox approved in Hong Kong 2 pages 139.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 October 2018 about the approval of Penthrox in Hong Kong. It discusses regulatory approval, market expansion, and partnership agreements but does not contain financial statements, detailed financial analysis, or management discussion of financial results. The document is relatively short (4067 characters) and serves as a news announcement regarding product registration and market entry. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention any report being attached or published. The content is best classified as a general regulatory announcement about product approval and market development, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2018-10-22 English
Penthrox is approved in Saudi Arabia 2 pages 137.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 11 October 2018 about the approval of Penthrox in Saudi Arabia by the Saudi Food and Drug Administration. It discusses marketing authorization, product details, and company background. There are no financial statements, earnings data, or detailed financial analysis. The document is a regulatory announcement about product approval and market expansion, not a financial report or management discussion. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2018-10-10 English
MVP signs exclusive Penthrox deal for China 2 pages 127.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 8 October 2018 about Medical Developments International Limited entering into an exclusive distribution and license agreement with Daiichi Sankyo for Penthrox in China, Thailand, and Vietnam. It details the terms of the agreement, payments, and strategic partnership but does not contain financial statements, quarterly or annual results, or detailed financial analysis. It is a corporate announcement about a capital or business development deal rather than a financial report or regulatory filing. The content fits best under Capital/Financing Update (CAP) as it relates to a significant licensing and distribution agreement involving upfront and milestone payments, which impacts the company's capital and revenue prospects.
2018-10-07 English
Appendix 3B 12 pages 378.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, issue price, purpose of the issue, and compliance with ASX listing rules. It also includes calculations related to placement capacity under ASX rules 7.1 and 7.1A. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding the issuance of additional shares as part of a Dividend Reinvestment Plan. This type of document is specifically used to announce new share issues and capital changes. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement.
2018-10-04 English
Change of Director's Interest Notice 12 pages 384.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including the number of shares held before and after the change, nature of the interest, and dates of changes. This type of document is a formal notification of personal share transactions by company directors. It is not a financial report, earnings release, or management discussion, but specifically reports insider trades by directors. Therefore, it fits the category of Director's Dealing (DIRS). The document length and detail confirm it is the actual notice, not just an announcement or certification.
2018-10-04 English
Change in substantial holding 3 pages 57.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001 Section 671B. It details changes in voting power and relevant interests of a substantial shareholder, including dates, share counts, and nature of changes. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2018-10-04 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.